Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Nervous System Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Site
Nervous System Neoplasm

Cancer Family

Nervous System Neoplasm

CI-CAN-00000038Explore in graph →

Non-malignant1,523 active trials9 approved drugs210 evidence items

NCIt: C3268
MeSH: D009423

Overview
Statistics
Survival
Genomics48
Variants & evidence210
Drugs47
Trials5871
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (168)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 126–150 of 168 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

BET bromodomain inhibition triggers apoptosis of NF1-associated malignant peripheral nerve sheath tumors through Bim induction.
· Cell Rep · 2014 · PMID 24373973 · validated civic_curation pubmed
Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain.
· PLoS Med · 2006 · PMID 17177598 · validated civic_curation pubmed
The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects.
· Clin Cancer Res · 2016 · PMID 26733615 · validated civic_curation pubmed
Poly (ADP) ribose polymerase inhibition: A potential treatment of malignant peripheral nerve sheath tumor.
· Cancer Biol Ther · 2016 · PMID 26650448 · validated civic_curation pubmed
Rare but Recurrent ROS1 Fusions Resulting From Chromosome 6q22 Microdeletions are Targetable Oncogenes in Glioma.
· Clin Cancer Res · 2018 · PMID 30171048 · validated civic_curation pubmed
Establishment and application of a novel patient-derived KIAA1549:BRAF-driven pediatric pilocytic astrocytoma model for preclinical drug testing.
· Oncotarget · 2017 · PMID 28002790 · validated civic_curation pubmed
Tyrosine receptor kinase B is a drug target in astrocytomas.
· Neuro Oncol · 2017 · PMID 27402815 · validated

Showing 126–150 of 168 publications

← Previous
1
…
5
6
7
Next →

civic_curation

Preclinical Test of Dacomitinib, an Irreversible EGFR Inhibitor, Confirms Its Effectiveness for Glioblastoma.

· Mol Cancer Ther · 2015 · PMID 25939761 · validated civic_curation pubmed

Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastoma.

· Proc Natl Acad Sci U S A · 2012 · PMID 22203985 · validated civic_curation pubmed

Overcoming resistance to single-agent therapy for oncogenic BRAF gene fusions via combinatorial targeting of MAPK and PI3K/mTOR signaling pathways.

· Oncotarget · 2017 · PMID 29156677 · validated civic_curation pubmed

Barthel & Johnson et al. Nature 2019

· 2019 · PMID 31748746 · validated cbioportal_study pubmed

Ankush et al. Clin Cancer Res 2024

· 2024 · PMID 37910594 · validated cbioportal_study pubmed

Zhao et al. Nat Med 2019

· 2019 · PMID 30742119 · validated cbioportal_study pubmed

Wang et al. Cell 2021

· 2021 · PMID 33577785 · validated cbioportal_study pubmed

Cloughesy et al. Nat Med. 2019

· 2019 · PMID 30742122 · validated cbioportal_study pubmed

Vaubel et al. Clin Cancer Res 2020

· 2020 · PMID 31852831 · validated cbioportal_study pubmed

TCGA, Nature 2008

· 2008 · PMID 18772890 · validated cbioportal_study pubmed

TCGA, Cell 2013

· 2013 · PMID 24120142 · validated cbioportal_study pubmed

Miller et al. Nature 2019

· 2019 · PMID 30675060 · validated cbioportal_study pubmed

Jonsson et al. Clin Cancer Res 2019

· 2019 · PMID 31263031 · validated cbioportal_study pubmed

Fisher, M. J. et al. Acta neuropathologica 2021

· 2021 · PMID 33585982 · validated cbioportal_study pubmed

Johnson et al. Science 2014

· 2014 · PMID 24336570 · validated cbioportal_study pubmed

TCGA, Cell 2016

· 2016 · PMID 26824661 · validated cbioportal_study pubmed

Pugh et al. Nature 2012

· 2012 · PMID 22820256 · validated cbioportal_study pubmed

Northcott et al. Nature 2017

· 2017 · PMID 28726821 · validated cbioportal_study pubmed